Research Analysts’ Weekly Ratings Updates for Karyopharm Therapeutics (KPTI)

Several analysts have recently updated their ratings and price targets for Karyopharm Therapeutics (NASDAQ: KPTI):

• 7/31/2026 – Karyopharm Therapeutics was downgraded by HC Wainwright from “buy” to “negative”.
• 7/31/2026 – Karyopharm Therapeutics had its price target lowered by Piper Sandler to $7.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – Karyopharm Therapeutics was downgraded by Robert W. Baird from “outperform” to “neutral”. They now have a $3.00 price target on the stock.
• 7/31/2026 – Karyopharm Therapeutics had its “neutral” rating reaffirmed by HC Wainwright. They now have a $3.00 price target on the stock, down from $13.00.
• 7/28/2026 – Karyopharm Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 7/21/2026 – Karyopharm Therapeutics had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $16.00 price target on the stock.
• 7/7/2026 – Karyopharm Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/18/2026 – Karyopharm Therapeutics had its “buy” rating reaffirmed by HC Wainwright.

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.